ACVR1 and fibrodysplasia ossificans progressiva: Therefore, anti‐ALK2 antibodies, such as the novel humanized monoclonal antibody DS‐6016a, may be clinically useful therapeutic agents for FOP, with possible utility for the prophylactic suppression of ectopic ossification.